Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chinook Therapeutics
Seattle, Washington, United Stateschinooktx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Chinook has two Phase 3 assets in development for IgA Nephropathy: atrasentan (an oral endothelin A receptor antagonist) with pivotal readout expected in Q3 2023, and zigakibart/BION-1301 (an anti-APRIL monoclonal antibody) which entered Phase 3 in July 2023. Atrasentan has shown significant reductions in proteinuria in clinical trials.
- Therapeutic areas
- Rare DiseasesNephrology
- Modalities
- Small moleculesMonoclonal antibodiesPrecision medicines
- Industry
- Biotech
02
Partnerships
AbbVie (in-licensed atrasentan)
Beyond the preview
Go deeper on Chinook Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chinook Therapeutics.